{"transactions":[{"id":686,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-02T20:30:29.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":650000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-08-31","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001871145-26-000006","document":"form4-09022026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871145/000187114526000006/form4-09022026_040901.xml","form_type":"4"}},{"id":702781,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-27T23:30:05.000Z","date":"2026-07-24","kind":"sale","planned":false,"acquired":false,"shares":12500,"price":11.714,"value":146425.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":702770,"source":{"system":"sec-edgar","filing":"0001831410-26-000008","document":"form4-07272026_070701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000008/form4-07272026_070701.xml","form_type":"4"}},{"id":702780,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-27T23:30:05.000Z","date":"2026-07-23","kind":"sale","planned":false,"acquired":false,"shares":12500,"price":11.579,"value":144737.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":715270,"source":{"system":"sec-edgar","filing":"0001831410-26-000008","document":"form4-07272026_070701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000008/form4-07272026_070701.xml","form_type":"4"}},{"id":729691,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-23T21:52:00.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"security","element":"securityTitle","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common stock, $0.0001 par value","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0000921895-26-001653","document":"form407422010_06232026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001653/form407422010_06232026.xml","form_type":"4"}},{"id":728554,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T21:30:23.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001831410-26-000006","document":"form4-06232026_090619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000006/form4-06232026_090619.xml","form_type":"4"}},{"id":728765,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:29:12.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001222082-26-000004","document":"form4-06232026_090608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000122208226000004/form4-06232026_090608.xml","form_type":"4"}},{"id":728684,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:28:25.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001533228-26-000008","document":"form4-06232026_090620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533228/000153322826000008/form4-06232026_090620.xml","form_type":"4"}},{"id":728552,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:27:31.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001821194-26-000002","document":"form4-06232026_090627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000182119426000002/form4-06232026_090627.xml","form_type":"4"}},{"id":728713,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:26:35.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001336504-26-000006","document":"form4-06232026_090631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650426000006/form4-06232026_090631.xml","form_type":"4"}},{"id":728551,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35886,"kind":"person","name":"Larson Yi","position":1,"cik":"0001785987","reported_name":"Larson Yi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:25:45.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001785987-26-000002","document":"form4-06232026_090642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000178598726000002/form4-06232026_090642.xml","form_type":"4"}},{"id":729130,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:24:48.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001638709-26-000004","document":"form4-06232026_090644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000163870926000004/form4-06232026_090644.xml","form_type":"4"}},{"id":728550,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:23:53.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0002018686-26-000010","document":"form4-06232026_090648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000201868626000010/form4-06232026_090648.xml","form_type":"4"}},{"id":729458,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36082,"kind":"person","name":"RAPPAPORT ANDREW","position":1,"cik":"0001162157","reported_name":"RAPPAPORT ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:22:35.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001162157-26-000002","document":"form4-06232026_090631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162157/000116215726000002/form4-06232026_090631.xml","form_type":"4"}},{"id":728549,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:21:15.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001777517-26-000002","document":"form4-06232026_090610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000177751726000002/form4-06232026_090610.xml","form_type":"4"}},{"id":797794,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-29T23:53:41.000Z","date":"2026-04-28","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in a series of 36 successive equal monthly installments measured from April 28, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":24150,"derivative":{"exercise_price":14.59,"expiration_date":"2036-04-27","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0002018686-26-000006","document":"form4-04292026_110437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000201868626000006/form4-04292026_110437.xml","form_type":"4"}},{"id":797793,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-29T23:53:41.000Z","date":"2026-04-28","kind":"grant","planned":false,"acquired":true,"shares":2911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on June 11, 2026, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":2911,"derivative":{"exercise_price":14.59,"expiration_date":"2036-04-27","underlying":"Common Stock","underlying_shares":2911},"source":{"system":"sec-edgar","filing":"0002018686-26-000006","document":"form4-04292026_110437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000201868626000006/form4-04292026_110437.xml","form_type":"4"}},{"id":857711,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":410000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857710,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":435000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857709,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Comon Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":233,"price":24.69,"value":5752.77,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $24.69, and the range of prices were between $24.68 and $24.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857708,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":24767,"price":24.25,"value":600599.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $24.25, and the range of prices were between $23.68 and $24.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":233,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857707,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":4.37,"value":109250.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857706,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-03","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":23.01,"value":345150.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $23.01, and the range of prices were between $22.89 and $23.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":857705,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-05T20:00:07.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":4.37,"value":65550.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001749432-26-000004","document":"form4-03052026_080301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000004/form4-03052026_080301.xml","form_type":"4"}},{"id":900283,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":66144,"kind":"person","name":"Austin Sasha Lu","position":1,"cik":"0002110895","reported_name":"Austin Sasha Lu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Finance and Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-18T02:35:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":29250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":29250,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":29250},"source":{"system":"sec-edgar","filing":"0002110895-26-000005","document":"form4-02182026_020201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000211089526000005/form4-02182026_020201.xml","form_type":"4"}},{"id":900282,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":66144,"kind":"person","name":"Austin Sasha Lu","position":1,"cik":"0002110895","reported_name":"Austin Sasha Lu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Finance and Controller"}}],"security":"Common Stock","published_at":"2026-02-18T02:35:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16188,"source":{"system":"sec-edgar","filing":"0002110895-26-000005","document":"form4-02182026_020201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000211089526000005/form4-02182026_020201.xml","form_type":"4"}},{"id":918937,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Performance Stock Options (Right to Buy)","published_at":"2026-02-05T02:30:10.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":106250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date."}],"balance_after":106250,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":106250},"source":{"system":"sec-edgar","filing":"0001905871-26-000002","document":"form4-02042026_090207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587126000002/form4-02042026_090207.xml","form_type":"4"}},{"id":918936,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T02:30:10.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":250000,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001905871-26-000002","document":"form4-02042026_090207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587126000002/form4-02042026_090207.xml","form_type":"4"}},{"id":918935,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Performance Stock Options (Right to Buy)","published_at":"2026-02-05T02:30:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":106250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date."}],"balance_after":106250,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":106250},"source":{"system":"sec-edgar","filing":"0001831216-26-000005","document":"form4-02042026_090205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000005/form4-02042026_090205.xml","form_type":"4"}},{"id":918934,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T02:30:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":250000,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001831216-26-000005","document":"form4-02042026_090205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000005/form4-02042026_090205.xml","form_type":"4"}},{"id":918933,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67695,"kind":"person","name":"Bohen Sean","position":1,"cik":"0001831218","reported_name":"Bohen Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Performance Stock Options (Right to Buy)","published_at":"2026-02-05T02:30:04.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Notwithstanding the foregoing, if the Reporting Person's continuous service is terminated without Cause (as defined in the Reporting Person's offer letter), the performance-based stock options shall remain outstanding and eligible to vest for twelve (12) months following such termination."}],"balance_after":275000,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001831218-26-000002","document":"form4-02042026_090201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121826000002/form4-02042026_090201.xml","form_type":"4"}},{"id":918932,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67695,"kind":"person","name":"Bohen Sean","position":1,"cik":"0001831218","reported_name":"Bohen Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T02:30:04.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":850000,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001831218-26-000002","document":"form4-02042026_090201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121826000002/form4-02042026_090201.xml","form_type":"4"}},{"id":918939,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Options (Right to Buy)","published_at":"2026-02-04T21:30:06.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date."}],"balance_after":56250,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001749432-26-000002","document":"form4-02042026_090203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000002/form4-02042026_090203.xml","form_type":"4"}},{"id":918938,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:30:06.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":220000,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001749432-26-000002","document":"form4-02042026_090203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000174943226000002/form4-02042026_090203.xml","form_type":"4"}},{"id":934006,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T02:00:05.000Z","date":"2026-01-20","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":26.88,"value":268800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"2. The weighted average sale price for the transaction reported was $26.88, and the range of prices were between $26.85 and $26.96. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":727770,"source":{"system":"sec-edgar","filing":"0001831410-26-000004","document":"form4-01212026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000004/form4-01212026_090101.xml","form_type":"4"}},{"id":936722,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-17T02:00:06.000Z","date":"2026-01-14","kind":"sale","planned":false,"acquired":false,"shares":3489,"price":29.12,"value":101599.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $29.12, and the range of prices were between $29.00 and $29.23. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":737770,"source":{"system":"sec-edgar","filing":"0001831410-26-000002","document":"form4-01162026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000002/form4-01162026_090101.xml","form_type":"4"}},{"id":938316,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":69321,"kind":"person","name":"Kovacs Shane William Charles","position":1,"cik":"0001579397","reported_name":"Kovacs Shane William Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. OPERATING & FINANCIAL OFF."}}],"security":"Common Stock","published_at":"2026-01-15T21:00:06.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":28.73,"value":2873000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average purchase price for the transaction reported was $28.73, and the range of prices were between $28.50 and $29.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":139727,"source":{"system":"sec-edgar","filing":"0001579397-26-000002","document":"form4-01152026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579397/000157939726000002/form4-01152026_090101.xml","form_type":"4"}},{"id":938315,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":69321,"kind":"person","name":"Kovacs Shane William Charles","position":1,"cik":"0001579397","reported_name":"Kovacs Shane William Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. OPERATING & FINANCIAL OFF."}}],"security":"Common Stock","published_at":"2026-01-15T21:00:06.000Z","date":"2026-01-13","kind":"sale","planned":false,"acquired":false,"shares":3822,"price":28.01,"value":107054.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.01, and the range of prices were between $28.00 and $28.03. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":239727,"source":{"system":"sec-edgar","filing":"0001579397-26-000002","document":"form4-01152026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579397/000157939726000002/form4-01152026_090101.xml","form_type":"4"}},{"id":939044,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":4.87,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939043,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":4.87,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939042,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"sale","planned":false,"acquired":false,"shares":35003,"price":28.99,"value":1014736.97,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":542761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939041,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"sale","planned":false,"acquired":false,"shares":14997,"price":28.6,"value":428914.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":577764,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939040,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":4.87,"value":243500.0,"ownership":{"direct":true},"balance_after":592761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939039,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"sale","planned":false,"acquired":false,"shares":200,"price":28.49,"value":5698.0,"ownership":{"direct":true},"balance_after":542761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939038,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"sale","planned":false,"acquired":false,"shares":49800,"price":27.6,"value":1374480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":542961,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939037,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":4.87,"value":243500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4."}],"balance_after":592761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939036,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":28.34,"value":283400.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Myles Properties Inc., of which the Reporting Person is President."}],"balance_after":144846,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":956970,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67695,"kind":"person","name":"Bohen Sean","position":1,"cik":"0001831218","reported_name":"Bohen Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-30T21:05:14.000Z","date":"2025-12-26","kind":"gift","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the gift of common stock to a charitable donor advised fund."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":237650,"source":{"system":"sec-edgar","filing":"0001831218-25-000004","document":"form4-12302025_091209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121825000004/form4-12302025_091209.xml","form_type":"4"}},{"id":957857,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T02:55:05.000Z","date":"2025-12-22","kind":"sale","planned":false,"acquired":false,"shares":2881,"price":28.53,"value":82194.93,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.53, and the range of prices was between $28.50 and $28.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":741259,"source":{"system":"sec-edgar","filing":"0001831410-25-000007","document":"form4-12292025_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000007/form4-12292025_091201.xml","form_type":"4"}},{"id":959425,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":false,"shares":12070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":12080,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":12070},"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959424,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":false,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.84,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959423,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":false,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.61,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959422,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":false,"shares":209690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.406,"expiration_date":"2023-08-11","underlying":"Common Stock","underlying_shares":209690},"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959421,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":41840,"price":30.48,"value":1275283.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $30.48, and the range of prices was between $30.23 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959420,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":193056,"price":29.71,"value":5735693.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $29.71, and the range of prices was between $29.22 and $30.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":41840,"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959419,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":29904,"price":28.83,"value":862132.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.83, and the range of prices was between $28.215 and $29.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":234896,"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959418,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":true,"shares":12070,"price":4.08,"value":49245.6,"ownership":{"direct":true},"balance_after":264800,"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959417,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":true,"shares":21520,"price":7.84,"value":168716.8,"ownership":{"direct":true},"balance_after":252730,"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959416,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":true,"shares":21520,"price":3.61,"value":77687.2,"ownership":{"direct":true},"balance_after":231210,"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959415,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T02:42:34.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":true,"shares":209690,"price":4.406,"value":923894.14,"ownership":{"direct":true},"balance_after":209690,"source":{"system":"sec-edgar","filing":"0001336504-25-000009","document":"form4-12242025_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000133650425000009/form4-12242025_021230.xml","form_type":"4"}},{"id":959290,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"gift","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":542881,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":959289,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":6046,"price":31.39,"value":189783.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $31.39, and the range of prices was between $31.00 and $31.595. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":551881,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":959288,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":43729,"price":30.4,"value":1329361.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $30.40, and the range of prices was between $30.00 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided"}],"balance_after":557927,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":959287,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":1225,"price":28.08,"value":34398.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.08, and the range of prices was between $28.075 and $28.130. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 11, 2024, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be understated by 60 shares. That error has been corrected in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":601656,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":959302,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":156818,"derivative":{"exercise_price":7.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959301,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":7182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":206818,"derivative":{"exercise_price":7.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":7182},"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959300,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":42818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":112182,"derivative":{"exercise_price":15.25,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":42818},"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959299,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":155000,"derivative":{"exercise_price":15.25,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959298,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-23","kind":"sale","planned":false,"acquired":false,"shares":99509,"price":27.66,"value":2752418.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $27.66, and the range of prices was between $27.50 and $27.83. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":4488,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959297,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":7.02,"value":351000.0,"ownership":{"direct":true},"balance_after":103997,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959296,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-22","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":28.04,"value":2804000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $28.04, and the range of prices was between $27.655 and $28.36. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":53997,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959295,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":7182,"price":7.02,"value":50417.64,"ownership":{"direct":true},"balance_after":153997,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959294,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":42818,"price":15.25,"value":652974.5,"ownership":{"direct":true},"balance_after":146815,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959293,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":12921,"price":28.93,"value":373804.53,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $28.93, and the range of prices was between $28.51 and $29.44. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":103997,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959292,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":57079,"price":28.03,"value":1599924.37,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $28.03, and the range of prices was between $27.50 and $28.49. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":116918,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":959291,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-24T02:40:55.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":15.25,"value":610000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":173997,"source":{"system":"sec-edgar","filing":"0001905871-25-000004","document":"form4-12242025_021251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000190587125000004/form4-12242025_021251.xml","form_type":"4"}},{"id":975579,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":69321,"kind":"person","name":"Kovacs Shane William Charles","position":1,"cik":"0001579397","reported_name":"Kovacs Shane William Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. OPERATING & FINANCIAL OFF."}}],"security":"Common Stock","published_at":"2025-12-09T21:00:09.000Z","date":"2025-12-08","kind":"gift","planned":false,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred 75,000 shares to the Kovacs 2025 Family Trust as a bona fide gift for no consideration. The reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust."}],"balance_after":243549,"source":{"system":"sec-edgar","filing":"0001579397-25-000007","document":"form4-12092025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579397/000157939725000007/form4-12092025_091203.xml","form_type":"4"}},{"id":984833,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":69321,"kind":"person","name":"Kovacs Shane William Charles","position":1,"cik":"0001579397","reported_name":"Kovacs Shane William Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. OPERATING & FINANCIAL OFF."}}],"security":"Common Stock","published_at":"2025-12-01T21:00:05.000Z","date":"2025-11-26","kind":"gift","planned":false,"acquired":false,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred 225,000 shares to the Kovacs 2025 Family Trust as a bona fide gift for no consideration. The reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust."}],"balance_after":318549,"source":{"system":"sec-edgar","filing":"0001579397-25-000005","document":"form4-12012025_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579397/000157939725000005/form4-12012025_091201.xml","form_type":"4"}},{"id":989014,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36082,"kind":"person","name":"RAPPAPORT ANDREW","position":1,"cik":"0001162157","reported_name":"RAPPAPORT ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T23:00:11.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":35868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.39,"expiration_date":"2025-12-20","underlying":"Common Stock","underlying_shares":35868},"source":{"system":"sec-edgar","filing":"0001162157-25-000005","document":"form4-11252025_061101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1162157/000116215725000005/form4-11252025_061101.xml","form_type":"4"}},{"id":989013,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36082,"kind":"person","name":"RAPPAPORT ANDREW","position":1,"cik":"0001162157","reported_name":"RAPPAPORT ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:00:11.000Z","date":"2025-11-25","kind":"gift","planned":false,"acquired":false,"shares":35868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred 35,868 to the Rappaport Family Foundation, a charitable foundation of which the reporting person is an officer, as a bona fide gift for no consideration. The reporting person has voting and dispositive power over all securities owned by the foundation."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001162157-25-000005","document":"form4-11252025_061101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1162157/000116215725000005/form4-11252025_061101.xml","form_type":"4"}},{"id":989012,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36082,"kind":"person","name":"RAPPAPORT ANDREW","position":1,"cik":"0001162157","reported_name":"RAPPAPORT ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:00:11.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":35868,"price":0.39,"value":13988.52,"ownership":{"direct":true},"balance_after":35868,"source":{"system":"sec-edgar","filing":"0001162157-25-000005","document":"form4-11252025_061101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162157/000116215725000005/form4-11252025_061101.xml","form_type":"4"}},{"id":1036060,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":3086,"price":8.32,"value":25675.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $8.32, and the range of prices was between $8.29 and $8.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager."}],"balance_after":117028,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1036059,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":1914,"price":8.08,"value":15465.12,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $8.08, and the range of prices was between $8.04 and $8.08. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager."}],"balance_after":120114,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1036058,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":8.33,"value":83300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $8.33, and the range of prices was between $8.28 and $8.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":744140,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1036057,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":8.04,"value":80400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $8.04, and the range of prices was between $8.02 and $8.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":754140,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1112496,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Stock Option (Right to buy)","published_at":"2025-06-13T22:23:00.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common stock, $0.0001 par value","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0000921895-25-001761","document":"form407422010_06132025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525001761/form407422010_06132025.xml","form_type":"4"}},{"id":1110979,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35886,"kind":"person","name":"Larson Yi","position":1,"cik":"0001785987","reported_name":"Larson Yi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:33.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017240","document":"form4-06132025_050629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925017240/form4-06132025_050629.xml","form_type":"4"}},{"id":1111106,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:30.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017239","document":"form4-06132025_050626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533228/000141588925017239/form4-06132025_050626.xml","form_type":"4"}},{"id":1111598,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":14722,"kind":"person","name":"Horning Sandra","position":1,"cik":"0001638709","reported_name":"Horning Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:27.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017238","document":"form4-06132025_050624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638709/000141588925017238/form4-06132025_050624.xml","form_type":"4"}},{"id":1111203,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:26.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017237","document":"form4-06132025_050621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000141588925017237/form4-06132025_050621.xml","form_type":"4"}},{"id":1110978,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:23.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017236","document":"form4-06132025_050619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925017236/form4-06132025_050619.xml","form_type":"4"}},{"id":1110977,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:21.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017235","document":"form4-06132025_050617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925017235/form4-06132025_050617.xml","form_type":"4"}},{"id":1110976,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017234","document":"form4-06132025_050615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925017234/form4-06132025_050615.xml","form_type":"4"}},{"id":1111290,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:16.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017233","document":"form4-06132025_050612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000141588925017233/form4-06132025_050612.xml","form_type":"4"}},{"id":1112174,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":36082,"kind":"person","name":"RAPPAPORT ANDREW","position":1,"cik":"0001162157","reported_name":"RAPPAPORT ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:13.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017232","document":"form4-06132025_050610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162157/000141588925017232/form4-06132025_050610.xml","form_type":"4"}},{"id":1235077,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T21:20:52.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":205000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001415889-25-006160","document":"form4-03032025_090348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925006160/form4-03032025_090348.xml","form_type":"4"}},{"id":1235076,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67697,"kind":"person","name":"Zojwalla Naseem","position":1,"cik":"0001905871","reported_name":"Zojwalla Naseem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T21:19:32.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":205000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001415889-25-006158","document":"form4-03032025_090328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925006158/form4-03032025_090328.xml","form_type":"4"}},{"id":1235075,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67695,"kind":"person","name":"Bohen Sean","position":1,"cik":"0001831218","reported_name":"Bohen Sean","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T21:15:14.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":650000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001415889-25-006147","document":"form4-03032025_090310.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925006147/form4-03032025_090310.xml","form_type":"4"}},{"id":1235078,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":62492,"kind":"person","name":"Mitchell Shawnte","position":1,"cik":"0001749432","reported_name":"Mitchell Shawnte","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T16:18:17.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":450000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-006154","document":"form4-03032025_090314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749432/000141588925006154/form4-03032025_090314.xml","form_type":"4"}},{"id":1235212,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":69321,"kind":"person","name":"Kovacs Shane William Charles","position":1,"cik":"0001579397","reported_name":"Kovacs Shane William Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. OPERATING & FINANCIAL OFF."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T16:16:48.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":320000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001415889-25-006151","document":"form4-03032025_090344.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579397/000141588925006151/form4-03032025_090344.xml","form_type":"4"}},{"id":1303908,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Pre-Funded Warrant","published_at":"2025-01-14T23:38:56.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":22740,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the \"Exchange Agreement\"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the \"Pre-Funded Warrants\"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":336288,"derivative":{"exercise_price":0.0001,"underlying":"Common stock, $0.0001 par value","underlying_shares":22740},"source":{"system":"sec-edgar","filing":"0000921895-25-000106","document":"form407422010_01142025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189525000106/form407422010_01142025.xml","form_type":"4"}}],"next_cursor":"2025-01-14T23:38:56.000000Z,1303908"}